MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

被引:68
作者
Melguizo, Consolacion [1 ,2 ]
Prados, Jose [1 ,2 ]
Gonzalez, Beatriz [3 ]
Ortiz, Raul [1 ,4 ]
Concha, Angel [5 ]
Juan Alvarez, Pablo [1 ]
Madeddu, Roberto [6 ,7 ]
Perazzoli, Gloria [1 ]
Antonio Oliver, Jaime [1 ]
Lopez, Rodrigo [5 ]
Rodriguez-Serrano, Fernando [1 ,2 ]
Aranega, Antonia [1 ,2 ]
机构
[1] Inst Biopathol & Regenerat Med IBIMER, Granada 18100, Spain
[2] Univ Granada, Dept Anat & Embriol, Granada 18012, Spain
[3] Virgen de las Nieves Hosp, Med Oncol Serv, Granada 18014, Spain
[4] Univ Jaen, Dept Hlth Sci, Jaen 23071, Spain
[5] Virgen de las Nieves Hosp, Serv Anatomopathol, Granada 18014, Spain
[6] Univ Sassari, Dept Biomed Sci Histol, I-07100 Sassari, Italy
[7] INBB, Natl Inst Biostruct & Biosyst, Sassari, Italy
关键词
Glioblastoma; Radiotherapy; Temozolomide; MGMT; Methylation; CD133; NEWLY-DIAGNOSED GLIOBLASTOMA; CANCER STEM-CELL; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ADJUVANT TEMOZOLOMIDE; PHASE-III; CONCOMITANT; SURVIVAL; GENE; HYPERMETHYLATION; CHEMOTHERAPY;
D O I
10.1186/1479-5876-10-250
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The CD133 antigen is a marker of radio-and chemo-resistant stem cell populations in glioblastoma (GBM). The O-6-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic significance of the CD133 antigen and promoter methylation and protein expression of MGMT in a homogenous group of GBM patients uniformly treated with radiotherapy and TMZ. The possible connection between these GBM markers was also investigated. Methods: Seventy-eight patients with GBM treated with radiotherapy combined with concomitant and adjuvant TMZ were analyzed for MGMT and CD133. MGMT gene promoter methylation was determined by methylation-specific polymerase chain reaction after bisulfite treatment. MGMT and CD133 expression was assessed immunohistochemically using an automatic quantification system. Overall and progression-free survival was calculated according to the Kaplan-Meier method. Results: The MGMT gene promoter was found to be methylated in 34 patients (44.7%) and unmethylated in 42 patients (55.3%). A significant correlation was observed between MGMT promoter methylation and patients' survival. Among the unmethylated tumors, 52.4% showed low expression of MGMT and 47.6% showed high-expression. Among methylated tumors, 58.8% showed low-expression of MGMT and 41.2% showed high-expression. No correlation was found between MGMT promoter methylation and MGMT expression, or MGMT expression and survival. In contrast with recent results, CD133 expression was not a predictive marker in GBM patients. Analyses of possible correlation between CD133 expression and MGMT protein expression or MGMT promoter methylation were negative. Conclusions: Our results support the hypothesis that MGMT promoter methylation status but not MGMT expression may be a predictive biomarker in the treatment of patients with GBM. In addition, CD133 should not be used for prognostic evaluation of these patients. Future studies will be necessary to determine its clinical utility.
引用
收藏
页数:11
相关论文
共 53 条
[21]   MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study [J].
Kim, Young Suk ;
Kim, Se Hoon ;
Cho, Jaeho ;
Kim, Jun Won ;
Chang, Jong Hee ;
Kim, Dong Suk ;
Lee, Kyu Sung ;
Suh, Chang-Ok .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03) :661-667
[22]   O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation [J].
Kreth, Simone ;
Thon, Niklas ;
Eigenbrod, Sabina ;
Lutz, Juergen ;
Ledderose, Carola ;
Egensperger, Rupert ;
Tonn, Joerg C. ;
Kretzschmar, Hans A. ;
Hinske, Ludwig C. ;
Kreth, Friedrich W. .
PLOS ONE, 2011, 6 (02)
[23]   Analysis of gene expression and chemoresistance of CDI33+ cancer stem cells in glioblastoma [J].
Liu, Gentao ;
Yuan, Xiangpeng ;
Zeng, Zhaohui ;
Tunici, Patrizia ;
Ng, Hiushan ;
Abdulkadir, Iman R. ;
Lu, Lizhi ;
Irvin, Dwain ;
Black, Keith L. ;
Yu, John S. .
MOLECULAR CANCER, 2006, 5 (1)
[24]   RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA [J].
MACDONALD, DR ;
CASCINO, TL ;
SCHOLD, SC ;
CAIRNCROSS, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1277-1280
[25]   Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution [J].
Metellus, Philippe ;
Nanni-Metellus, Isabelle ;
Delfino, Christine ;
Colin, Carole ;
Tchogandjian, Aurelie ;
Coulibaly, Bema ;
Fina, Frederic ;
Loundou, Anderson ;
Barrie, Marylin ;
Chinot, Olivier ;
Ouafik, L'Houcine ;
Figarella-Branger, Dominique .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (10) :2937-2945
[26]   Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide [J].
Minniti, Giuseppe ;
Salvati, M. ;
Arcella, A. ;
Buttarelli, F. ;
D'Elia, A. ;
Lanzetta, G. ;
Esposito, V. ;
Scarpino, S. ;
Enrici, R. Maurizi ;
Giangaspero, F. .
JOURNAL OF NEURO-ONCOLOGY, 2011, 102 (02) :311-316
[27]   Stem cell-related "Self-Renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma [J].
Murat, Anastasia ;
Migliavacca, Eugenia ;
Gorlia, Thierry ;
Lambiv, Wanyu L. ;
Shay, Tal ;
Hamou, Marie-France ;
de Tribolet, Nicolas ;
Regli, Luca ;
Wick, Wolfgang ;
Kouwenhoven, Mathilde C. M. ;
Hainfellner, Johannes A. ;
Heppner, Frank L. ;
Dietrich, Pierre-Yves ;
Zimmer, Yitzhak ;
Cairncross, J. Gregory ;
Janzer, Robert-Charles ;
Domany, Eytan ;
Delorenzi, Mauro ;
Stupp, Roger ;
Hegi, Monika E. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) :3015-3024
[28]   Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas [J].
Nakagawa, Takao ;
Ido, Kazunori ;
Sakuma, Takahiro ;
Takeuchi, Hiroaki ;
Sato, Kazufumi ;
Kubota, Toshihiko .
NEUROPATHOLOGY, 2009, 29 (04) :379-388
[29]   Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas [J].
Nakasu, S ;
Fukami, T ;
Baba, K ;
Matsuda, M .
JOURNAL OF NEURO-ONCOLOGY, 2004, 70 (03) :333-340
[30]   Prognostic significance of loss of O6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma [J].
Nakasu, Satoshi ;
Fukami, Tadateru ;
Jito, Jyunya ;
Matsuda, Masayuki .
SURGICAL NEUROLOGY, 2007, 68 (06) :603-609